Qishen Granule Protects against Doxorubicin-Induced Cardiotoxicity by Coordinating MDM2-p53-Mediated Mitophagy and Mitochondrial Biogenesis

被引：11

作者：

Li W. ^{[1
]}

Zhang Y. ^{[1
]}

Wang X. ^{[1
]}

Cao J. ^{[1
]}

Qian W. ^{[2
]}

Ling G. ^{[1
]}

Tan N. ^{[1
]}

Jiang J. ^{[1
]}

Sun Q. ^{[1
]}

Li C. ^{[3
]}

Wang W. ^{[1
,4
,5
,6
]}

Wang Y. ^{[1
,4
,5
]}

机构：

[1] School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing

[2] Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi University of Chinese Medicine, Xianyang

[3] Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing

[4] Beijing Key Laboratory of TCM Syndrome and Formula, Beijing University of Chinese Medicine, Beijing

[5] Key Laboratory of TCM Syndrome and Formula, Beijing University of Chinese Medicine), Ministry of Education, Beijing

[6] Guangzhou University of Chinese Medicine, Guangzhou

来源：

Oxidative Medicine and Cellular Longevity | 2022年 / 2022卷

基金：

中国国家自然科学基金;

关键词：

All Open Access; Gold; Green;

D O I：

10.1155/2022/4344677

中图分类号：

学科分类号：

摘要：

Doxorubicin (DOX), the anthracycline chemotherapeutic agent, is widely used for the treatment of various cancers. However, its clinical application is compromised by dose-dependent and fatal cardiotoxicity. This study is aimed at investigating the cardioprotective effects of Qishen granule (QSG) and the specific mechanism by which QSG alleviates DOX-induced cardiotoxicity (DIC) and providing an alternative for the treatment of DIC. We first evaluated the cardioprotective effects of QSG in a DIC mouse model, and the obtained results showed that QSG significantly protected against DOX-induced myocardial structural and functional damage, mitochondrial oxidative damage, and apoptosis. Subsequently, after a comprehensive understanding of the specific roles and recent developments of p53-mediated mitochondrial quality control mechanisms in DIC, we investigated whether QSG acted on MDM2 to regulate the activity of p53 and downstream mitophagy and mitochondrial biogenesis. The in vivo results showed that DOX inhibited mitochondrial biogenesis and blocked mitophagy in the mouse myocardium, while QSG reversed these effects. Mechanistically, we combined nutlin-3, which inhibits the binding of p53 and MDM2, with DOX and QSG and evaluated their influence on mitophagy and mitochondrial biogenesis in H9C2 cardiomyocytes. The obtained results showed that both DOX and nutlin-3 substantially inhibited mitophagy and mitochondrial biogenesis and induced mitochondrial oxidative damage and apoptosis, which could be partially recovered by QSG. Importantly, the immunoprecipitation results showed that QSG promoted the binding of MDM2 to p53, thus decreasing the level of p53 protein and the binding of p53 to Parkin. Collectively, QSG could promote the degradation of p53 by enhancing the binding of MDM2 to the p53 protein, resulting in the reduced binding of p53 to the Parkin protein, thus improving Parkin-mediated mitophagy. Increased degradation of p53 protein by QSG simultaneously enhanced mitochondrial biogenesis mediated by PGC-1α. Ultimately, QSG relieved DOX-induced mitochondrial oxidative damage and apoptosis by coordinating mitophagy and mitochondrial biogenesis. Copyright © 2022 Weili Li et al.

引用

共 45 条

[1]

Bonadonna G., Monfardini S., de Lena M., Fossati-Bellani F., Beretta G., Phase I and preliminary phase II evaluation of adriamycin (NSC 123127), Cancer Research, 30, 10, pp. 2572-2582, (1970)

[2]

Hortobagyi G.N., Anthrazykline in der Krebstherapie, Drugs, 54, pp. 1-7, (1997)

[3]

Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A., A clinicopathologic analysis of adriamycin cardiotoxicity, Cancer, 32, 2, pp. 302-314, (1973)

[4]

Lipshultz S.E., Scully R.E., Lipsitz S.R., Et al., Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial, The Lancet Oncology, 11, 10, pp. 950-961, (2010)

[5]

Tebbi C.K., London W.B., Friedman D., Et al., Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease, Journal of Clinical Oncology, 25, 5, pp. 493-500, (2007)

[6]

Wenningmann N., Knapp M., Ande A., Vaidya T.R., Ait-Oudhia S., Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring, Molecular Pharmacology, 96, 2, pp. 219-232, (2019)

[7]

Renu K., Abilash V.G., Tirupathi Pichiah P.B., Arunachalam S., Molecular mechanism of doxorubicin-induced cardiomyopathy - an update, European Journal of Pharmacology, 818, pp. 241-253, (2018)

[8]

Wallace K.B., Sardao V.A., Oliveira P.J., Mitochondrial determinants of doxorubicin-induced cardiomyopathy, Circulation Research, 126, 7, pp. 926-941, (2020)

[9]

Picca A., Mankowski R.T., Burman J.L., Et al., Mitochondrial quality control mechanisms as molecular targets in cardiac ageing, Nature Reviews Cardiology, 15, 9, pp. 543-554, (2018)

[10]

Ni H.-M., Williams J.A., Ding W.-X., Mitochondrial dynamics and mitochondrial quality control, Redox Biology, 4, pp. 6-13, (2015)

← 1 2 3 4 5 →